4.7 Review

USP7: Novel Drug Target in Cancer Therapy

期刊

FRONTIERS IN PHARMACOLOGY
卷 10, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2019.00427

关键词

deubiquitination; USP7; structure; immune; DNA damage

资金

  1. National Natural Science Foundation of China [81602961, 81430085, 81773562]
  2. Outstanding Young Talent Research Fund of Zhengzhou University [1521331002]
  3. National Key Research Program of Proteins [2016YFA0501800, 2017YFD0501401]
  4. Key Research Program of Henan Province [161100310100]

向作者/读者索取更多资源

Ubiquitin specific protease 7 (USP7) is one of the deubiquitinating enzymes (DUB) that erases ubiquitin and protects substrate protein from degradation. Full activity of USP7 requires the C-terminal Ub-like domains fold back onto the catalytic domain, allowing the remodeling of the active site to a catalytically competent state by the C-terminal peptide. Until now, numerous proteins have been identified as substrates of USP7, which play a key role in cell cycle, DNA repair, chromatin remodeling, and epigenetic regulation. Aberrant activation or overexpression of USP7 may promote oncogenesis and viral disease, making it a target for therapeutic intervention. Currently, several synthetic small molecules have been identified as inhibitors of USP7, and applied in the treatment of diverse diseases. Hence, USP7 may be a promising therapeutic target for the treatment of cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据